Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 18/20 | 0.54 |
| ▸ | SMARCA2 | P51531 | 16/20 | 0.54 |
| ▸ | SMARCA4 | P51532 | 16/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29704251 | 1.00 | PBRM1 (0.54) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL22776334 | 0.93 | PBRM1 (0.57) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL30796567 | 0.93 | PBRM1 (0.57) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704373 | 0.89 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704347 | 0.89 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL25110979 | 0.89 | SMARCA2 (0.51) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL25109818 | 0.89 | SMARCA2 (0.51) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL22794165 | 0.87 | SMARCA2 (0.58) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL22794370 | 0.86 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL22794880 | 0.86 | SMARCA2 (0.49) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-03 | — | — | US | disclosed |
| EP-4259144-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | PBRM1 13/4885SMARCA2 3/4885SMARCA4 5/4885 |
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | PBRM1 11/4885SMARCA2 4/4885SMARCA4 7/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PBRM1 11/4885SMARCA2 4/4885SMARCA4 5/4885 |
| US-20250109138-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PBRM1 126/4885SMARCA2 2/4885SMARCA4 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.